• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Improved hepatitis C drugs may increase healthcare costs

byMoises GallegosandSai Folmsbee
March 17, 2015
in Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Simulation studies for the new hepatitis C virus (HCV) treatments sofosbuviir and ledispavir show gains in cost-effectiveness, but may be associated with an increased total cost over the next five years.

Evidence Rating Level: 2 (Good)       

Study Rundown: The FDA recently approved 3 new drugs for the treatment of HCV, including the first combination RNA polymerase and protease inhibitor sofosbuvir-ledipasvir. These drugs have many benefits, including avoiding interferon-associated toxicity, a superior sustained virologic response, shorter treatment duration, and fewer adverse effects. However, sofosbuvir-ledipasvir is expensive, about $1125/day. To determine its cost-effectiveness, this study utilized a microsimulation model for HCV to estimate costs for these new treatment regimens compared to old standards. From this, treating 10 000 patients with new therapies was predicted to prevent 600 cases of decompensated cirrhosis, 310 cases of hepatocellular carcinoma (HCC), 60 liver transplants, and 550 liver related deaths. The cost of treatment with sofosbuvir-ledipasvir ranged from $66 000-$154 000, compared to $15 000-$71 600 for old standards, leading to an estimated additional cost of $65 billion over the next five years for third party payers. However, this study was limited by the uncertainty in the evidence for treatment used by the model, as some studies included for analysis were not randomized, did not directly compare new drugs, or were internationally based. Analysis was also limited in that changes in health care insurance resulting from the Patient Protection and Affordable Care Act were not considered. Overall, at current pricing, this analysis suggests that new therapies may increase the cost of HCV.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Infectious Diseases Society of America Recommendations for testing, Managing, and Treating Hepatitis C

In-Depth [simulation study]: A Markov-based state transition model was used to simulate the course of 120 patient profiles receiving each of old standard therapies and sofosbuvir-ledipasvir. Treatment outcomes were based on recent clinical trials, and treatment windows were between 8 and 48 weeks. Weekly costs of sofosbuvir and ledipasvir were $7000 and $875 respectively. Pegylated interferon, ribavirin, boceprevir, and telaprevir were priced at $587, $309, $1100, and $4100 per week, respectively. Sofosbuvir-ledipasvir demonstrated an average 0.56 increment in per-person quality-adjusted life-year (QALY), from 10.07 old standards to 10.63. At a $50 000 willingness-to-pay threshold, sofosbuvir-ledipasvir was predicted to be cost effective in 82% of treatment-naĂŻve patients and 60% of treatment-experienced patients, and rose to 83% and 81%, respectively, at $100 000. The incremental cost-effectiveness ratio for sofosbuvir-ledipasvir was $54 000 per additional QALY gained in comparison with old standards of care. The authors estimated that 1.6 million persons in the US would be eligible for treatment in the next 5 years, requiring payers to cover $136 billion in costs ($61 billion by the government), with new drugs costing an additional $65 billion.

RELATED REPORTS

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

Cancer screening costs in the United States may exceed $40 billion annually

Appendicitis hospitalization care costs higher among patients with delayed diagnosis of appendicitis

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: healthcare costshepatitis C
Previous Post

Novel HCV treatment may be cost-effective for some genotypes

Next Post

Decrease in foreign-born tuberculosis linked to culture-based screening

RelatedReports

Study lends support for interferon-free treatment of hepatitis C
2 Minute Medicine

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

November 29, 2024
Patient Basics: Colonoscopy
Oncology

Cancer screening costs in the United States may exceed $40 billion annually

August 14, 2024
Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis
Public Health

Appendicitis hospitalization care costs higher among patients with delayed diagnosis of appendicitis

April 27, 2024
#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
StudyGraphics

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

September 7, 2023
Next Post
Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]

Decrease in foreign-born tuberculosis linked to culture-based screening

Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis

Agreement between pathologists on interpretation of breast biopsies about 75%

Racial differences in colorectal cancer survival linked to health at initial diagnosis

NSAID use effect on colorectal cancer risk influenced by genetics

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.